XHKG
0399
Market cap21mUSD
May 05, Last price
0.07HKD
Name
Innovative Pharmaceutical Biotech Ltd
Chart & performance
P/E
—
P/S
78.86
EPS
—
Div yield, %
—
Shrs. gr., 5y
3.38%
Rev. gr., 5y
-32.19%
Revenues
2m
-68.28%
Net income
-346m
L
CFO
-11m
L+27.49%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating as an investment holding company, Innovative Pharmaceutical Biotech Limited (IPBL) primarily engages in the distribution of beauty equipment and associated products across both mainland China and Hong Kong. The firm structures its operations into two key divisions: Trading of Beauty Products and Research and Development. Furthermore, IPBL's diversified activities include securities investments, the development and market introduction of oral insulin products, the provision of bio-industrial goods, and offering genetic screening services. The company rebranded to Innovative Pharmaceutical Biotech Limited in September 2015, having previously been known as United Gene High-Tech Group Limited. Its principal office is located in Sheung Wan, Hong Kong.
Key people
Executive Chairman of the Board · since 2025
Peilun Li
Chief Technology Officer · since 2025
Yuan Xing Gao
Executive Director · since 2016
Fan Long
Executive Director · since 2025
Shujuan Qi
Executive Director · since 2025
Rong Tang
Executive Director · since 2014
Ming Wu
Executive Director · since 2025
Shen Zhang
Executive Director · since 2025
Hon Yin Poon
Financial Controller, Company Secretary · since 2013
Weijun Chen
Independent Non-Executive Director, · since 2009
Rongliang Wang
Independent Non-Executive Director, · since 2011
Yi Zhang
Non-Executive Director · since 2025
Jinzhong Chen
Independent Non-Executive Director, · since 2021
Sizheng Sun
Non-Executive Independent Director · since 2025
Independent Non-Executive Director · since 2025
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||